Association of albumin –bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib

ConclusionALBI was strongly associated with the prognosis of patients with mCRC treated with regorafenib and with the occurrence of liver-related adverse events. These findings may imply that patients with a high ALBI score should not be treated with regorafenib.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research